Evidence map›Paper›PMID 41127521›Full record

ReviewFrontiers in endocrinology2025

The emerging role of extracellular vesicles in diabetes and complications: mechanistic insights and translational prospects.

Siyuan Liu, Zhicheng Pan, Xuzhuo Chen, Zhenlin Wang, Wei Zhong, Jitao Ling, Yixuan Chen, Panpan Xia, Deju Zhang, Xiao Liu and 3 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Siyuan LiuDepartment of Endocrinology and Metabolism, The Second Affiliated Hospital, Nanchang University, Nanchang, China.
Zhicheng PanThe Second Clinical Medical College of Nanchang University, Nanchang, Jiangxi, China.
Xuzhuo ChenThe Second Clinical Medical College of Nanchang University, Nanchang, Jiangxi, China.
Zhenlin WangThe First Clinical Medical College of Nanchang University, Nanchang, Jiangxi, China.
Wei ZhongThe First Clinical Medical College of Nanchang University, Nanchang, Jiangxi, China.
Jitao LingDepartment of Endocrinology and Metabolism, The Second Affiliated Hospital, Nanchang University, Nanchang, China.
Yixuan ChenDepartment of Anesthesiology, The Second Affiliated Hospital, Nanchang University, Nanchang, China.
Panpan XiaDepartment of Endocrinology and Metabolism, The Second Affiliated Hospital, Nanchang University, Nanchang, China.
Deju ZhangFood and Nutritional Sciences, School of Biological Sciences, The University of Hong Kong, Hong Kong, , Hong Kong SAR, China.
Xiao LiuDepartment of Cardiology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
Peng YuDepartment of Endocrinology and Metabolism, The Second Affiliated Hospital, Nanchang University, Nanchang, China.
Zhen HuDepartment of Ultrasound, The Second Affiliated Hospital, Nanchang University, Nanchang, China.
Jing ZhangDepartment of Anesthesiology, The Second Affiliated Hospital, Nanchang University, Nanchang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Extracellular vesicles (EVs), particularly exosomes, have emerged as key players in diabetes pathogenesis, diagnosis, and therapy. They regulate intercellular communication, influence islet function, and contribute to diabetic complications such as retinopathy, nephropathy, and cardiomyopathy. Their potential as liquid biopsy biomarkers and engineered therapeutic carriers-delivering nucleic acids, proteins, or stem cell-derived regenerative signals-offers promising avenues for diabetes management. However, there are some critical challenges in clinical translation. Future research must prioritize (1) scalable GMP-compliant production with rigorous quality control, (2) targeted delivery systems via ligand modification or biomimetic engineering, (3) improved biocompatibility through cargo optimization and stealth coatings, and (4) large-scale clinical trials to validate efficacy and safety. Addressing these hurdles is essential to harness EVs' full potential and accelerate their transition into mainstream diabetic care.

Indexed as

Diabetes ComplicationsDiabetes MellitusExtracellular VesiclesTranslational Research, BiomedicalAnimalsCell CommunicationHumansbiomarkerscell-cell communicationdiabetes mellitusdiabetic complicationsexosomesextracellular vesiclesliquid biopsytargeted therapy

Identifiers

PMID41127521
PMCPMC12537412

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.